Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline includes Lenzetto, Evamist, Testosterone Topical Solution, and others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
36
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,173.60 | 36.60 | -0.40% |
| CAC 40 | 8,262.70 | 11.87 | -0.14% |
| DAX 40 | 24,154.47 | 87.77 | 0.36% |
| Dow JONES (US) | 48,578.72 | 115.00 | 0.24% |
| FTSE 100 | 10,589.99 | 30.41 | 0.29% |
| HKSE | 26,394.26 | 521.94 | 2.02% |
| NASDAQ | 24,102.70 | 86.69 | 0.36% |
| Nikkei 225 | 59,518.34 | 1,640.95 | 2.84% |
| NZX 50 Index | 13,105.67 | 39.61 | 0.30% |
| S&P 500 | 7,041.28 | 18.33 | 0.26% |
| S&P/ASX 200 | 8,955.00 | 56.40 | -0.63% |
| SSE Composite Index | 4,055.55 | 28.34 | 0.70% |